fda spravato - Search News

FDA Approves ‘Spravato’ Nasal Spray

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

FDA approves Spravato, nasal spray derived from Ketamine

The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.

UPI News on MSN · 1d

FDA approves Spravato, first monotherapy nasal spray to treat depression

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,

Hosted on MSN1d

J&J’s Spravato receives FDA label expansion for depression monotherapy

Johnson & Johnson’s (J&J) nasal spray Spravato (esketamine) has received a label expansion, now approved as a monotherapy ...

J&J’s Spravato Makes Headway in Tough Depression Space With Monotherapy Approval

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

Global Health Watch: Key Updates and Challenges

This summary covers the latest health-related news, including FDA's approval of Spravato as a standalone depression treatment ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results